Wall Street analysts expect Bicycle Therapeutics Limited (NASDAQ:BCYC) to report earnings of ($0.54) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Bicycle Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.47) and the lowest estimate coming in at ($0.59). The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Bicycle Therapeutics will report full-year earnings of ($3.18) per share for the current fiscal year, with EPS estimates ranging from ($3.30) to ($3.06). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.26) per share, with EPS estimates ranging from ($2.71) to ($1.58). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Bicycle Therapeutics.
Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.05. The firm had revenue of $0.61 million during the quarter, compared to the consensus estimate of $1.00 million. Bicycle Therapeutics had a negative net margin of 342.94% and a negative return on equity of 238.49%.
A number of institutional investors have recently added to or reduced their stakes in BCYC. Monashee Investment Management LLC acquired a new position in shares of Bicycle Therapeutics in the 2nd quarter worth approximately $532,000. Pentwater Capital Management LP bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at $642,000. Laurion Capital Management LP bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at $1,006,000. Victory Capital Management Inc. acquired a new stake in shares of Bicycle Therapeutics during the second quarter worth $1,403,000. Finally, Atlas Venture Advisors Inc. acquired a new stake in shares of Bicycle Therapeutics during the second quarter worth $13,709,000. Hedge funds and other institutional investors own 36.27% of the company’s stock.
Shares of Bicycle Therapeutics stock traded down $0.31 during trading on Friday, hitting $8.30. The company’s stock had a trading volume of 12,584 shares, compared to its average volume of 13,177. Bicycle Therapeutics has a 52 week low of $6.24 and a 52 week high of $14.91. The firm’s 50-day moving average is $9.10.
Bicycle Therapeutics Company Profile
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
Recommended Story: What is a dividend reinvestment plan?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.